---
id: trial_001
type: clinical_trial
topic: Obesity treatment
disease: Obesity
molecule: Tirzepatide
phase: Phase 3
status: Completed
---

Trial: SURMOUNT-1 - Tirzepatide for Obesity Management

Sponsor: Eli Lilly
Enrollment: 2,539 patients
Duration: 72 weeks
Population: Adults with BMI ≥30 or ≥27 with weight-related comorbidity

Primary Endpoint: Percent change in body weight from baseline
Results: 
- Tirzepatide 5mg: -15.0% weight reduction
- Tirzepatide 10mg: -19.5% weight reduction  
- Tirzepatide 15mg: -20.9% weight reduction
- Placebo: -3.1% weight reduction

Secondary Endpoints:
- ≥5% weight loss achieved by 91% (15mg) vs 35% (placebo)
- ≥20% weight loss achieved by 57% (15mg) vs 3% (placebo)
- Improvements in waist circumference, blood pressure, lipids

Safety:
- Nausea (24-33%), diarrhea (18-23%), constipation (11-17%)
- Discontinuation due to AEs: 4.3-7.1% vs 2.6% placebo
- No pancreatitis signal detected

Conclusion: Tirzepatide demonstrates unprecedented weight loss efficacy in obesity, positioning it as a potential best-in-class therapy. FDA approval received May 2024.

